Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H27N5O2 |
Molecular Weight | 453.5356 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCOC1=CC=C(C=C1)C2=NC(=C(N2)C3=CC4=C(C=C3)C(CC4)=NO)C5=CC=NC=C5
InChI
InChIKey=MLSAQOINCGAULQ-QFMPWRQOSA-N
InChI=1S/C27H27N5O2/c1-32(2)15-16-34-22-7-3-19(4-8-22)27-29-25(18-11-13-28-14-12-18)26(30-27)21-5-9-23-20(17-21)6-10-24(23)31-33/h3-5,7-9,11-14,17,33H,6,10,15-16H2,1-2H3,(H,29,30)/b31-24+
Molecular Formula | C27H27N5O2 |
Molecular Weight | 453.5356 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16260133Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17145850
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16260133
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17145850
SB-590885 is a selective b-Raf inhibitor, developed by GlaxoSmithKline. It inhibited proliferation of BRAF-mutated cells in vitro and slowed down tumor growth in mouse xenograft model of melanoma.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18621524
Curator's Comment: Known to be CNS non-penetrant in rats. Human data not available.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16260133
Curator's Comment: # GlaxoSmithKline Pharmaceuticals
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5145 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16260133 |
0.3 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17145850
In a mouse xenograft model, SB-590885 was administered by i.p. injections at 50 mg/kg.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17145850
For a proliferation assay, cancer cell lines were treated with SB-590885 in 0.1% DMSO and incubated for 72 hours at 37°C, 5% CO2. Viable cells were quantified using CellTiter-Glo reagent and luminescence detection on a Victor 2V plate reader. SB-590885 inhibits proliferation of BRAF-mutated cells with IC50 0.1 - 0.87 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:14:06 GMT 2023
by
admin
on
Sat Dec 16 02:14:06 GMT 2023
|
Record UNII |
ISE5ATW631
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135564599
Created by
admin on Sat Dec 16 02:14:06 GMT 2023 , Edited by admin on Sat Dec 16 02:14:06 GMT 2023
|
PRIMARY | |||
|
ISE5ATW631
Created by
admin on Sat Dec 16 02:14:06 GMT 2023 , Edited by admin on Sat Dec 16 02:14:06 GMT 2023
|
PRIMARY | |||
|
405554-55-4
Created by
admin on Sat Dec 16 02:14:06 GMT 2023 , Edited by admin on Sat Dec 16 02:14:06 GMT 2023
|
PRIMARY | |||
|
DTXSID001025861
Created by
admin on Sat Dec 16 02:14:06 GMT 2023 , Edited by admin on Sat Dec 16 02:14:06 GMT 2023
|
PRIMARY |